This study looks at how the drug **MK-3475 (Pembrolizumab)** affects women with triple negative breast cancer (TNBC), which is a type of cancer that doesn't have estrogen, progesterone, or HER2 receptors. The study is open to women aged 21 and older who have a breast tumor less than 3 cm and no cancer spread to other parts. They must not have had any cancer treatment before joining the study.
The study involves taking two doses of Pembrolizumab before surgery to see if it changes the tumor or nearby tissues. Researchers are interested in how the immune system reacts to the treatment. Participants must agree to use birth control during the study and meet specific health criteria, like being infection-free and not pregnant.
- The study lasts until surgery after two doses of the drug.
- Participants may not have prior cancer treatments.
- Compensation details are not specified in the study information.
How understandable was the trial content above?
Hard to understand
Easy to understand